It doesn't induce or inhibit the cytochrome P450 enzymes that metabolize estrogen and progestin
Chen, D., Liang, H., Huang, L., Zhou, H
GLP-1 and Amylin in the Treatment of Obesity
In the SUSTAIN clinical trial program, semaglutide at the 1.0 mg weekly dose reduced HbA1c by 1.5% to 1.8% over 30 to 56 weeks of treatment
Clinical trial data consistently shows the cagrilintide semaglutide mix produces average weight loss of 25% of total body weight over 68 weeks, greatly exceeding the 15-17% achieved with semaglutide alone and surpassing all other now available weight loss drugs
Additionally, studies have shown that other medical difficulties and a gradual increase in Older adults may also be at a high risk of experiencing side effects of medications or interactions among multiple medications that could lead to dizziness and falls